NCT02106104View on ClinicalTrials.gov

Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Type 2 Diabetes
Interventions
DRUG

Linagliptin 5 mg QD (N=24)

Linagliptin 5 mg will be taken orally, once daily for 8 weeks

DRUG

Glimepiride 1 mg QD (N=24)

Glimepiride 1 mg will be taken orally, once daily for 8 weeks

Trial Locations (1)

1081 HV

VU University Medical Center, Amsterdam

All Listed Sponsors
lead

Amsterdam UMC, location VUmc

OTHER

NCT02106104 - Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes | Biotech Hunter | Biotech Hunter